Novo Nordisk CSO Says R&D Revamp Reflects New Stem Cell And AI Focus
Executive Summary
Mads Krogsgaard Thomsen tells Scrip that recent successes in stem cell research and the on-going advances in artificial intelligence helped prompt the Danish group to revamp its R&D activities.